Blockade of the CD47/SIRPα Checkpoint Potentiates the Anti-Tumor Efficacy of Tafasitamab

被引：3
|
作者：
Mangelberger, Doris
Augsberger, Christian
Landgraf, Karin
Heitmuller, Christina
Steidl, Stefan
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-139582
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Dual CD47 and PD-L1 blockade elicits anti-tumor immunity by intratumoral CD8+ T cells
    Christo, Susan N.
    Mcdonald, Keely M.
    Burn, Thomas N.
    Kurd, Nadia
    Stanfield, Jessica
    Kaneda, Megan M.
    Seelige, Ruth
    Dillon, Christopher P.
    Fisher, Timothy S.
    Baaten, Bas
    Mackay, Laura K.
    CLINICAL & TRANSLATIONAL IMMUNOLOGY, 2024, 13 (11)
  • [42] Blockade of the Immune Checkpoint CD47 By TTI-621 Potentiates the Response to Anti-PD-L1 in Cutaneous T Cell Lymphoma
    Han, Zhen
    Wu, Xiwei
    Yuan, Yate-Ching
    Qin, Hanjun
    Su, Chingyu
    Zain, Jasmine
    Akilov, Oleg E.
    Rosen, Steve T.
    Feng, Mingye
    Querfeld, Christiane
    BLOOD, 2022, 140 : 6376 - 6377
  • [43] Dual regulation of SIRP α phosphorylation by integrins and CD47
    Johansen, Mette L.
    Brown, Eric J.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2007, 282 (33) : 24219 - 24230
  • [44] Enhancement of anti-tumor efficacy of immune checkpoint blockade by alpha-TEA
    Redmond, William L.
    Kasiewicz, Melissa J.
    Akporiaye, Emmanuel T.
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [45] Cancer immunotherapy targeting the CD47/SIRPα axis
    Weiskopf, Kipp
    EUROPEAN JOURNAL OF CANCER, 2017, 76 : 100 - 109
  • [46] Functional characterization of the selective pan-allele anti-SIRPα antibody ADU-1805 that blocks the SIRPα-CD47 innate immune checkpoint
    Voets, Erik
    Parade, Marc
    Hulsik, David Lutje
    Spijkers, Sanne
    Janssen, Wout
    Rens, Joost
    Reinieren-Beeren, Inge
    van den Tillaart, Gilbert
    van Duijnhoven, Sander
    Driessen, Lilian
    Habraken, Maurice
    van Zandvoort, Peter
    Kreijtz, Joost
    Vink, Paul
    van Elsas, Andrea
    van Eenennaam, Hans
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7 (01):
  • [47] Anti-angiogenic and anti-tumor properties of in silico-designed peptides from CD47
    Jeanne, A.
    Sick, E.
    Schneider, C.
    Floquet, N.
    Devy, J.
    Kaplan, H.
    Fichel, C.
    Bouland, N.
    Diebold, M. -D.
    Dauchez, M.
    Martiny, L.
    Dedieu, S.
    FEBS JOURNAL, 2012, 279 : 91 - 91
  • [48] DUAL CHECKPOINT BLOCKADE OF CD47 AND PD-L1 USING AN AFFINITY-TUNED BISPECIFIC ANTIBODY MAXIMIZES ANTI-TUMOR IMMUNITY AND IMPROVES THERAPEUTIC WINDOW
    Chen, Shih-Hsun
    Dominik, Pawel
    Stanfield, Jessica
    Ding, Sheng
    Yang, Wenjing
    Kurd, Nadia
    Llewellyn, Ryan
    Heyen, Jonathan
    Wang, Carole
    Melton, Zea
    Lindquist, Kevin
    Van Blarcom, Thomas
    Chaparro-Riggers, Javier
    Salek-Ardakani, Shahram
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A290 - A290
  • [49] Blocking CD47 Shows Superior Anti-tumor Therapeutic Effects of Bevacizumab in Gastric Cancer
    Shi, Chenyang
    Li, Jiaxin
    Fan, Guorong
    Liu, Yu
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [50] Inhibition of autophagy potentiated the anti-tumor effects of VEGF and CD47 bispecific therapy in glioblastoma
    Zhang, Xuyao
    Wang, Shaofei
    Nan, Yanyang
    Fan, Jiajun
    Chen, Wei
    Luan, Jingyun
    Wang, Yichen
    Liang, Yanxu
    Li, Song
    Tian, Wenzhi
    Ju, Dianwen
    APPLIED MICROBIOLOGY AND BIOTECHNOLOGY, 2018, 102 (15) : 6503 - 6513
12345